Salveen Richter, Goldman Sachs lead U.S. biotech analyst, joins ‘Squawk on the Street’ to discuss Amgen’s mid-stage trial results for its experimental obesity drug, why she remains bullish on the company, where to invest in GLP-1 stocks, and more.
Wednesday, November 27
Add A Comment